
## Marwan Kwok

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4303897/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The three musketeers: uniting against CLL. Blood, 2022, 139, 1264-1265.	0.6	0
2	Linking epigenome regulation with DNA repair. Blood, 2022, 139, 3356-3357.	0.6	0
3	Ibrutinib: another string to its bow. Blood, 2021, 137, 3461-3462.	0.6	1
4	Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers, 2021, 13, 4681.	1.7	9
5	Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discovery, 2021, 2, 13-18.	2.6	5
6	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. Frontiers in Oncology, 2021, 11, 790004.	1.3	11
7	Genetics in the era of targeted CLLÂtherapy. Blood, 2020, 135, 2333-2334.	0.6	1
8	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. Blood, 2020, 135, 411-428.	0.6	17
9	Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer. , 2019, , 203-230.		2
10	Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. Frontiers in Immunology, 2019, 10, 2832.	2.2	34
11	PALB2 variant status in hematological malignancies – a potential therapeutic target?. Leukemia and Lymphoma, 2019, 60, 1823-1826.	0.6	1
12	PB1946 OUTCOMES FOLLOWING TREATMENT DISCONTINUATION IN CML: REALâ€WORLD EXPERIENCE FROM 3 REGIONAL UK CENTRES. HemaSphere, 2019, 3, 884-885.	1.2	1
13	USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood, 2017, 130, 156-166.	0.6	60
14	Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget, 2017, 8, 44749-44760.	0.8	13
15	Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood, 2016, 128, 2770-2773.	0.6	106
16	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood, 2016, 127, 582-595.	0.6	214
17	Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet, The, 2015, 385, S58.	6.3	69
18	Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection?. Blood, 2015, 126, 167-167.	0.6	4

Marwan Kwok

#	Article	IF	CITATIONS
19	Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia. Lancet, The, 2014, 383, S66.	6.3	4
20	ATR Inhibition Exacerbates Replication Stress in TP53 or ATM Deficient CLL Cells and Enhances Sensitivity to Chemotherapy and Targeted Therapy. Blood, 2014, 124, 3340-3340.	0.6	1
21	CLL Progression Is Associated with Increased Clonal Diversity and Replication Stress. Blood, 2014, 124, 1977-1977.	0.6	0
22	Synthetic Lethality In CLL With DNA Damage Response Defect By Targeting ATR Pathway. Blood, 2013, 122, 120-120.	0.6	2
23	Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy Blood, 2009, 114, 540-540.	0.6	12
24	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2008, 359, 575-583.	13.9	518
25	Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year Blood, 2007, 110, 749-749.	0.6	1
26	Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia, 2005, 19, 1896-1904.	3.3	52